Improving the quality of the local pharmaceutical manufacturing sector would boost intracontinental trade and reduce the burden the pharmaceutical industry can place on the national balance of payments deficit, Adcock Ingram CEO Andy Hall said this week. Local pharmaceutical companies imported more than a third of their active ingredients, negatively affecting the balance of payments. Adcock said a R470m state incentive had enabled it to expand its Germiston and Clayville manufacturing facilities’ capacity to produce 2-billion capsules and tablets a year.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now